FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 350:2522-2524 June 10, 2004 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Swartz, M. N. PubMed Citation

To the Editor: In his review of cellulitis (Feb. 26 issue),¹ Swartz does not stress the effect that the emergence of community-acquired methicillin-resistant Staphylococcus aureus has had on treatment strategies for a "usual case of cellulitis" at many centers in the United States and elsewhere.^2,3,4 Methicillin-resistant S. aureus strains circulating among previously healthy persons in the community attending our medical center now constitute the majority of S. aureus isolates, and we have terminated our reliance on beta-lactams as initial therapy for putative community-acquired cellulitis due to infection with the resistant strain — the therapy Swartz suggests. We now use clindamycin . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.